Symbiotec recognizes Rs 53 crore DCV revenue in Q2 FY27

Symbiotec Pharmalab Limited recognized Rs 53 crore of dual-chamber vial milestone revenue in Q2 FY27, contributing to consolidated revenue of Rs 280 crore, up 43% year-on-year. The income followed a September 30 US agreement covering two complex injectable products, which management expects to commercialize in FY28.

What does Symbiotec’s US dual-chamber vial agreement cover?

Symbiotec’s September 30 agreement covers two complex injectable products for the US market that use its dual-chamber vial, or DCV, platform. Symbiotec will handle development, regulatory submissions, manufacturing and supply, while an unnamed global partner will undertake US commercialization and distribution.

The agreement has three disclosed revenue streams: development and regulatory milestones, eventual product-supply revenue, and a share of profits from the partner’s product sales. Management said supply revenue is likely to begin from the next fiscal year onward, while milestone recognition should continue on similar lines for the next couple of years.

Management described DCV as a format in which relatively few companies have developed commercial-scale generic-drug and contract development and manufacturing capabilities. Symbiotec is discussing other markets with the same partner and assessing opportunities in other geographies, but the signed agreement disclosed on November 6 relates only to the two US products.

How much DCV revenue did Symbiotec recognize in Q2 FY27?

Symbiotec recognized Rs 53 crore of DCV development and regulatory milestone revenue in Q2 FY27. Management said it invoiced completed milestones and received the amount during the quarter, while the chief financial officer said the revenue related to completed contractual milestones invoiced to partners.

The Rs 53 crore was included in consolidated Q2 FY27 revenue of Rs 280 crore, which increased 43% year-on-year. By comparison, the active pharmaceutical ingredient, or API, business generated Rs 227 crore in the quarter, growing 16% year-on-year through volume and product mix. The reported quarter therefore combined continuing API growth with newly recognized injectable milestone income.

Consolidated earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 94 crore in Q2 FY27 after adjusting for a one-time Rs 3 crore initial public offering expense charged to the profit-and-loss account. That compared with Rs 50 crore in the prior-year quarter. Profit after tax was Rs 52 crore, up 169% year-on-year.

When does Symbiotec expect the US products to commercialize?

Symbiotec expects the two DCV products to commercialize in FY28, according to management’s November 6 call. This is a management target rather than a confirmed launch date because regulatory filings, approvals, manufacturing and the partner’s commercialization work must precede sales.

Symbiotec filed the first abbreviated new drug application, or ANDA, for a DCV product with the US Food and Drug Administration in September. Management plans to file the second ANDA in the fourth quarter of FY27. The call did not disclose expected approval dates for either application.

The Rs 53 crore recognized in Q2 FY27 was pre-launch contractual income rather than revenue from product sales. Product-supply income will depend on later manufacturing and supply activity, while profit sharing will depend on the partner’s sales after commercialization. The company did not disclose the contractual split between milestones, supply revenue and profit share.

What additional injectable formats is Symbiotec developing?

Symbiotec has completed proof of concept for a dual-chamber bag, a second format based on the same platform as its DCV products. Management described the bag as a ready-to-use product for critical-care settings, but did not disclose a customer agreement, regulatory filing date or revenue forecast for it.

Symbiotec is also exploring testosterone injectable contract development and manufacturing opportunities. Management said this is a natural extension of its position in testosterone and other hormone APIs, but characterized the initiative as exploratory rather than a signed commercial programme.

The API platform remains the larger reported business. Symbiotec manufactures more than 60 steroid and hormone molecules and has filed 44 US Food and Drug Administration drug master files and holds 25 European certificates of suitability. API gross margins were above 60% in both Q2 and H1 FY27, while API EBITDA margins were around 30% in both periods.

How does the DCV milestone fit Symbiotec’s investment plan?

Symbiotec said it has invested more than Rs 1,000 crore in its new business verticals, including complex injectables and fermentation contract development and manufacturing. H1 FY27 capital expenditure was Rs 113 crore, while net debt was Rs 314 crore as of September 30.

Management said its focus has shifted to commissioning and execution after securing anchor agreements. For FY27, it maintained guidance for approximately 20% revenue growth and around 25% EBITDA growth, with a range of 5 percentage points on either side. This is management guidance, not a reported result.

The company also expects commercial batches under its 10-year US alternate-protein contract to begin in the first quarter of FY28. Its five-year insulin drug-substance contract is expected to be commissioned in Q4 FY27, with sales projected to commence in FY28 after regulatory approvals. These projects are separate from the two-product DCV agreement.

Conclusion

The Rs 53 crore DCV milestone shows that Symbiotec’s US injectable partnership has begun generating contractual revenue before product commercialization. It supported Q2 FY27 consolidated revenue growth of 43% to Rs 280 crore, alongside 16% growth in the Rs 227 crore API business. Future DCV economics, however, remain dependent on regulatory progress, product supply and partner sales.

The next disclosed DCV checkpoint is the planned second ANDA filing in Q4 FY27, followed by management’s FY28 commercialization target. Investors can also track recognition of further milestone revenue, delivery against guidance for about 20% FY27 revenue growth and 25% EBITDA growth, and commissioning of the insulin and fermentation projects.